Every Form 4 that Syndax Pharmaceuticals, Inc. (SNDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNDX filings page.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger reported an exercise-and-sale transaction in company common stock. He exercised stock options for 32,375 shares at $6.38 per share and sold 32,375 shares in open-market trades at an average of $24.2402 per share.
The sales were made under a pre-established Rule 10b5-1 trading plan. After these transactions, Metzger directly holds 484,843 common shares and retains 1,564,551 vested options that are immediately exercisable, plus 813,949 additional options that have not yet vested.
Syndax Pharmaceuticals Head of R&D and CMO Nicholas A.J. Botwood reported an exercise-and-sell pattern in company stock. On June 11–12, he exercised stock options to acquire a total of 53,750 shares of common stock at $13.82 per share and sold 65,515 shares in open-market transactions around $18 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 60,885 common shares and has 16,537 vested and 289,413 unvested options to purchase additional shares.
Syndax Pharmaceuticals Inc Chief Financial Officer Keith A. Goldan reported an open-market sale of 1,177 shares of common stock at $18.99 per share. According to the footnote, these shares were required to be sold to cover tax withholding obligations from the vesting of restricted stock units. Following the transaction, he held 139,252 shares directly, indicating this was a small, tax-related adjustment rather than a large discretionary sale.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger sold 6,847 shares of common stock in an open-market transaction. The shares were sold at an average price of $18.99 per share. According to the footnote, this sale was made to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 484,843 shares afterward.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger reported a sale of common stock primarily to cover taxes. On 02/09/2026, he sold 17,159 shares of Syndax Pharmaceuticals common stock at a price of $21.028 per share.
The filing explains that this sale represents shares required to be sold to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary open-market sale of his full holdings. After this transaction, Metzger beneficially owned 491,690 shares of Syndax Pharmaceuticals common stock in direct ownership.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported a sale of common stock tied to tax withholding. On February 9, 2026, he sold 3,410 shares of Syndax common stock at $21.028 per share.
According to the filing, this sale represents shares required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market sale. After this transaction, Goldan directly beneficially owns 140,429 shares of Syndax common stock.
Syndax Pharmaceuticals Chief Executive Officer and director Michael A. Metzger reported multiple equity transactions. On February 4, 2026, he received 73,000 restricted stock units that vest in three equal annual installments, plus 144,600 performance-based RSUs whose payout depends on pre-set metrics. He was also granted stock options for 440,000 shares at an exercise price of $20.43 per share, vesting monthly over four years. On February 6, 2026, he sold 7,412 shares of common stock at $20.62 per share to cover tax withholding tied to RSU vesting, and after these transactions directly owned 508,849 common shares and 440,000 options.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported multiple equity transactions in early 2026. He bought 1,219 shares of common stock on January 30, 2026 at $8.48 per share through the employee stock purchase plan, and now directly holds 143,839 common shares.
On February 4, 2026, he received 21,500 time-based restricted stock units and 30,750 performance-based RSUs, each convertible into one share of common stock upon vesting under service and, for the performance award, metric conditions. He also received 118,000 stock options with a $20.43 exercise price, vesting monthly over four years.
On February 6, 2026, Goldan sold 2,082 shares of common stock at $20.62 per share to cover tax withholding obligations related to RSU vesting, as disclosed, and continues to directly own both common shares and the newly granted options.
Syndax Pharmaceuticals director Jennifer Jarrett received an equity award linked to 24,000 shares of common stock on February 4, 2026. The award is in the form of restricted stock units that vest one year from the grant date.
After this grant, she beneficially owns 114,000 shares of Syndax common stock. The underlying shares cannot be delivered, transferred, or sold until vesting and certain events such as separation from service, death, disability, or a change in control.
Syndax Pharmaceuticals director Martin H. Huber Jr. received an award of 24,000 shares in the form of restricted stock units on February 4, 2026, at a price of $0 per share. After this grant, he beneficially owns 103,000 shares of common stock in direct form.
The restricted stock units vest one year from the grant date. The underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control of the company.
Syndax Pharmaceuticals granted equity awards to its Head of R&D and Chief Medical Officer, Nicholas A.J. Botwood, as part of his compensation on 02/04/2026. He received 24,000 time-based RSUs, each representing one share of common stock, which vest in three equal annual installments over three years, contingent on continued service.
He also received 36,000 performance-based RSUs, with shares issuable only if pre-established performance metrics approved by the Compensation Committee are achieved and he remains in service. In addition, he was granted 144,700 stock options with an exercise price of $20.43 per share, vesting in equal monthly installments over four years. All reported common stock awards were acquired at $0 per share, reflecting non-cash equity compensation.
Syndax Pharmaceuticals director Dennis Podlesak reported an equity award on this Form 4. On February 4, 2026, he was granted 48,000 restricted stock units at a price of $0 per share. These units vest one year from the grant date.
The shares underlying the restricted stock units will only be delivered, and may not be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control. After this grant, Podlesak beneficially owns 239,763 shares of common stock, held directly.
Syndax Pharmaceuticals director Aleksandra Rizo reported a grant of 24,000 shares of common stock on February 4, 2026. The award was made at a price of $0 per share and increased her beneficial ownership to 49,000 shares held directly.
The grant represents restricted stock units that vest one year from the grant date. The underlying shares will only be delivered, and therefore cannot be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control.
Syndax Pharmaceuticals director Keith Katkin reported an equity award of 24,000 shares of common stock in the form of restricted stock units (RSUs) on February 4, 2026. The award was granted at a price of $0 per share, increasing his beneficial ownership to 124,000 shares held directly.
The RSUs vest one year from the grant date. However, the underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control, creating a deferral feature on actual share delivery.
Syndax Pharmaceuticals director receives equity award. Director Pierre Legault was granted 24,000 shares of Syndax Pharmaceuticals common stock on February 4, 2026 as a stock award priced at $0 per share, increasing his beneficial ownership to 114,000 shares held directly.
The award is in the form of restricted stock units that vest one year from the grant date. The underlying shares cannot be delivered, transferred, or sold until vesting and the earlier of separation from service, death, disability, or a change in control.